There are currently 90 clinical trials in Riverside, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Kaiser Permanente-Riverside, GSK Investigational Site, Artemis Institute for Clinical Research and CITrials. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT05839041
Recruiting
Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atrophy secondary to age-related macular degeneration.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
03/11/2024
Locations: Kaiser Permanente, Riverside, California
Conditions: Geographic Atrophy of the Macula, Macular Degeneration
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/11/2024
Locations: Kaiser Permanente Riverside Medical Center, Riverside, California
Conditions: Intracerebral Hemorrhage
Register for Updates
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
NCT06176196
Recruiting
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2024
Locations: Probe Clinical Research, Riverside, California
Conditions: Painful Lumbosacral Radiculopathy
Register for Updates
Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy
NCT06215820
Recruiting
MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after bunionectomy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Investigator site 110, Riverside, California
Conditions: Acute Pain, Post Operative Pain, Pain
Register for Updates
Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy
NCT06215859
Recruiting
MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Investigator site 208, Riverside, California
Conditions: Acute Pain, Post Operative Pain, Pain
Register for Updates
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
NCT05393284
Recruiting
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2024
Locations: Retina Consultants of Southern California, Riverside, California +1 locations
Conditions: Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Register for Updates
Factors in Learning And Plasticity: Healthy Vision
NCT05439759
Recruiting
A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the National Eye Institute (NEI) to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the National Institute of M... Read More
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
02/21/2024
Locations: University of California, Riverside, Riverside, California
Conditions: Central Visual Impairment, Macular Degeneration
Register for Updates
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
NCT06179108
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives o... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: CenExel CIT Riverside, Riverside, California
Conditions: Schizophrenia
Register for Updates
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335
Recruiting
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2024
Locations: Reviva site, Riverside, California
Conditions: Schizophrenia
Register for Updates
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619
Recruiting
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
02/08/2024
Locations: Riverside Community Hospital, Riverside, California
Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Kaiser Permanente-Riverside, Riverside, California
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates